Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Colleen Plein

Otolaryngology Kenosha, WI Medical Doctor

NPI 1114248028 CMS profile 1325772

6127 Green Bay Rd Ste 100, Ste 300, Kenosha, WI 53142

Open in the dashboard

General payments

$16,273

312 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Colleen Plein of Kenosha, WI is reported in the CMS Open Payments database as having received $16,273 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,774 79
2024 General $7,761 72
2023 General $756 39
2022 General $1,235 56
2021 General $1,108 35
2020 General $475 12
2019 General $3,163 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Colleen Plein
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Colleen Plein were reported at $1,774. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Colleen Plein Otolaryngology median Middle half National median
2019 $3,163 $194 $82–$512 $163
2020 $475 $118 $42–$280 $114
2021 $1,108 $167 $63–$444 $132
2022 $1,235 $216 $84–$545 $149
2023 $756 $235 $93–$588 $160
2024 $7,761 $280 $111–$699 $164
2025 $1,774 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $7,344 58 payments
  2. OptiNose US, Inc. $3,484 46 payments
  3. GlaxoSmithKline, LLC. $1,667 91 payments
  4. Genzyme Corporation $1,256 47 payments
  5. Intersect ENT, Inc. $563 10 payments
  6. Medtronic, Inc. $500 9 payments
  7. Aerin Medical Inc. $329 9 payments
  8. Stryker Corporation $321 14 payments
  9. ALK-Abello, Inc $263 9 payments
  10. Watermark Medical, Inc. $119 1 payment
  11. Other $427 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,046 10 payments
  2. Food and Beverage $6,654 293 payments
  3. Travel and Lodging $1,357 6 payments
  4. Education $217 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $6,881 42 payments
  2. Xhance $3,484 46 payments
  3. DUPIXENT Immunology $1,693 60 payments
  4. NUCALA $1,667 91 payments
  5. DUPIXENT Immunology And Inflammation $463 16 payments
  6. SINUVA $418 7 payments
  7. XPRESS ENT DILATION SYSTEM $195 8 payments
  8. PROPEL $144 3 payments
  9. ARES HOME SLEEP TESTING DEVICE $119 1 payment
  10. ENTELLUS - XPRESS ENT DILATION SYSTEM $114 5 payments
  11. Other $1,283 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

108

Median for Otolaryngology: 297

Drug cost

$58,585

Median for Otolaryngology: $6,314

Branded share of claims

13.9%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 15 $56,804
Ipratropium Bromide Generic 44 $1,119
Fluticasone Propionate Generic 49 $662

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$55,605

Medicare's payments for the services billed

Medicare patients

92

Average age 70

Services billed

528

60 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 51%
Ischemic heart disease 23%
Depression 22%
Diabetes 16%
Osteoporosis 14%
Cancer 13%
Atrial fibrillation 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $6,547
  • GENZYME CORPORATION $442
$6,989 15 —
NUCALA
  • GlaxoSmithKline, LLC. $512
$512 — —
Xhance
  • OptiNose US, Inc. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record